Toronto/IBNS: With signs of the COVID-19 caseload poised to grow in the weeks ahead, three new vaccines are being reviewed by Health Canada designed to specifically target the XBB.1.5 Omicron subvariant now in widespread circulation.
Following a months-long review process of New mRNA vaccines from Pfizer and Moderna and a non-mRNA product from Novavax, supplies could reportedly start to roll out in the fall.
A Health Canada spokesperson reportedly said in a media statement there will be an “ample supply” of the new formulation of mRNA vaccines.
Pfizer shots are ready to be deployed as soon as regulators authorize their use, Pfizer CEO Albert Bourla has said.
Health Canada said that Novavax’s protein-based XBB COVID vaccine candidate would be unavailable until later this year and added that there is an option to receive this shot by people who are unwilling or unable to receive an mRNA vaccine.